Repaglinide
- Generic Name
- Repaglinide
- Brand Names
- Enyglid, Gluconorm, Prandin, NovoNorm, Repaglinide Krka, Repaglinide Accord, Repaglinide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N2O4
- CAS Number
- 135062-02-1
- Unique Ingredient Identifier
- 668Z8C33LU
- Background
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood ...
- Indication
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Target Recruit Count
- 30
- Registration Number
- NCT06601517
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-10-03
- Target Recruit Count
- 48
- Registration Number
- NCT06503679
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States
A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT06494761
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT06367153
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT06290050
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06165146
- Locations
- 🇺🇸
Covance Clinical Research Unit, Daytona Beach, Florida, United States
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-01-11
- Target Recruit Count
- 28
- Registration Number
- NCT06092931
- Locations
- 🇺🇸
ICON Phase 1 Clinic, Salt Lake City, Utah, United States
Voxelotor CYP and Transporter Cocktail Interaction Study
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT05981365
- Locations
- 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States
A Drug Interaction Study of LY3871801 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT05602675
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib
- Conditions
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 96
- Registration Number
- NCT05555823
- Locations
- 🇩🇪
Atriva study site, Neu-Ulm, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.